Brittany Knick Ragon

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study

Brittany Knick Ragon, Olatoyosi Odenike, Maria R. Baer et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 64 citations · Full text

Hematological Malignancy, Inhibitor Trametinib, Medicine +7

Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network

Carlos J. Gallego, Amber Burt, Agnes S. Sundaresan et al. · The American Journal of Human Genetics · 2015 · 63 citations · Full text

Hereditary Hemochromatosis, Genetics, Genetic Epidemiology +19

Lyme disease in France: a primary care-based prospective study

Laurent Letrilliart, Brittany Knick Ragon, Thomas Hanslik et al. · Epidemiology and Infection · 2005 · 61 citations · Full text

Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation

Olivia Copelan, Srinivasa Reddy Sanikommu, Jigar Trivedi et al. · Biology of Blood and Marrow Transplantation · 2018 · 60 citations · Full text

Transplant Rejection, Hemorrhagic Cystitis, Bk Virus +15

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias

Brittany Knick Ragon, Hagop M. Kantarjian, Elias Jabbour et al. · American Journal of Hematology · 2016 · 52 citations · Full text

Mixed-phenotype Acute Leukemia, Pathology, Pi3k Inhibitor +16